

## **IMAGION BIOSYSTEMS LIMITED**

(ASX: IBX)

29 October 2019

## Pro-Rata Renounceable Rights Issue – Amended Timetable

Imagion Biosystems Limited (ASX: IBX) announces an amendment to the proposed timetable for the Pro-Rata Renounceable Rights Issue as announced to the ASX on Monday, 28 October 2019.

| Particulars <sup>1</sup>   | Date (2019)           |
|--|-----------------------|
| Lodgement of Prospectus with ASIC and provision of copies to ASX   | Monday, 28 October    |
| Appendix 3B given to ASX   | Monday, 28 October    |
| Notice sent to security holders containing information required by Appendix 3B                                 | Tuesday, 29 October   |
| "Ex" date – existing shares are quoted on an ex basis and rights trading starts on a deferred settlement basis | Thursday, 31 October  |
| Record Date  | Friday, 1 November    |
| Prospectus and Entitlement and Acceptance Form sent to Eligible Shareholders                                   | Wednesday, 6 November |
| Rights trading ends  | Friday, 8 November    |
| Last Day to extend offer closing date  | Tuesday, 12 November  |
| Closing Date <sup>2</sup>  | Thursday, 14 November |
| ASX notified of under subscriptions  | Tuesday, 19 November  |
| Anticipated date for the issue of the Shares   | Thursday, 21 November |
| Normal trading of shares commence  | Friday, 22 November   |

## Notes:

-ENDS-

<sup>&</sup>lt;sup>1</sup> Indicative dates only.

<sup>&</sup>lt;sup>2</sup> Subject to the Listing Rules, the Directors reserve the right to extend the Closing Date for the Offer at their discretion. Any extension of the Closing Date will have a consequential effect on the anticipated date for issue of the Shares.



## **About Imagion Biosystems**

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:
Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations: Kyahn Williamson, WE Buchan ImagionBiosystems@we-buchan.com +61-3-9866-4722